Trials / Recruiting
RecruitingNCT05851443
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | povorcitinib | povorcitinib |
| OTHER | placebo | placebo |
| DRUG | ICS-LABA | Background Therapy |
Timeline
- Start date
- 2023-07-11
- Primary completion
- 2026-06-15
- Completion
- 2027-01-31
- First posted
- 2023-05-09
- Last updated
- 2026-04-14
Locations
83 sites across 7 countries: United States, Argentina, Canada, Germany, Japan, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05851443. Inclusion in this directory is not an endorsement.